Vorstand

PETER C. FARRELL

PhD, DSc, AM – Founder, Chairman and CEO

Peter Farrell is founder of ResMed and has been Chairman and a director of the Company since its inception in June 1989. Dr. Farrell also served as Chief Executive Officer from July 1990 until December 2007; from January, 2008 Dr. Farrell has served as Executive Chairman and from ResMed’s formation in 1989 until September 2004, Farrell was also ResMed’s President.

From July 1984 to June 1989, Dr. Farrell served as Vice President, Research and Development at various subsidiaries of Baxter International, Inc. (“Baxter”), and from August 1985 to June 1989, he also served as Managing Director of the Baxter Center for Medical Research Pty Ltd., a subsidiary of Baxter. From January 1978 to December 1989, he was Foundation Director of the Graduate School for Biomedical Engineering at the University of New South Wales where he currently serves as a Visiting Professor and as Chairman of the UNSW Centre for Innovation and Entrepreneurship.

Dr. Farrell also serves on three faculty Advisory Boards at UCSD: the Rady Business School, the Jacobs Engineering School and Health Sciences. He holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle and a D.Sc. from the University of New South Wales for research contributions in the field of treatment with the artificial kidney.

Dr. Farrell was named 1998 San Diego Entrepreneur of the Year for Health Sciences, Australian Entrepreneur of the Year in 2001 and US National Entrepreneur of the Year for 2005 in Health Sciences. In August 2000, he was named Vice Chairman of the Executive Council of the Harvard Medical School Division of Sleep Medicine; in July, 2010 Dr. Farrell became Chair of the Executive Council. In addition to his responsibilities with ResMed, Dr. Farrell is a director of NuVasive, Inc., a Nasdaq-listed company which develops and markets products for the surgical treatment of spine disorders and is non-executive chair of QRxPharma, a clinical-stage specialty pharmaceutical company listed on the ASX. He is a Fellow or Honorary Fellow of several professional bodies and is an active philanthropist, primarily through the Farrell Family Foundation. Dr. Farrell is also currently President of the Board of Trustees of the Museum of Contemporary Arts, San Diego.

DON DARKIN

President, SDB Strategic Business Unit

Don Darkin has been President, SDB Strategic Business unit since May 2011 and Sr. Vice President, Strategic Business Unit - Patient Interfaces since July 2007. Before these positions, Mr. Darkin held several senior roles within ResMed. He joined ResMed in August 1999 as Vice President, Product Development. In May 2005, he became Director of Operations in France for Ventilation, and subsequently served as Vice President, Business Divisions, and Senior Vice President, Global Product Development. Before working at ResMed, Mr. Darkin served as Vice President of Operations for Ambri Pty (Molecular Engineering and Biotechnology) Ltd. Australia, and Vice President, Product Development for Telectronics Medical Systems Australia and USA. Mr. Darkin is identified as an inventor or co-inventor on 81 granted patents worldwide. Mr. Darkin was educated in the U.K. in mechanical engineering and has further professional management training at University of New South Wales and Massachusetts Institute of Technology.

ROBERT DOUGLAS

President, Asia Pacific and Chief, Global Supply Operations

Rob Douglas has been President, Asia Pacific and Chief, Global Supply Operations since May 2011. He had been COO - Asia Pacific since July 2008. This appointment follows an extensive career within ResMed, his former roles including COO – Sydney from 2005 and Vice President of Operations from 2003 responsible for ResMed’s Australian manufacturing. Mr. Douglas first joined ResMed In 2001 in the role of Vice President of Corporate Marketing.

MICHAEL FARRELL

President, Americas

Michael J. Farrell joined ResMed in September 2000 and has been President, Americas since May 2011. Previously, Mr. Farrell was Sr. Vice President, Strategic Business Unit - Sleep from July 2007 to May 2011, and before that role Vice President, Marketing for the Americas from June 2005 through July 2007, and prior to that, Vice President, Business Development. Before joining ResMed, Mr. Farrell worked in management consulting and biotechnology, as well as in chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporation, The Dow Chemical Company, Vale and BHP Billiton. Mr. Farrell sits on the Board of Directors of the American Association for Homecare. Mr. Farrell holds a Bachelor of Engineering, with first-class honors, from the University of New South Wales, a Master of Science in Chemical Engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management.

JIM HOLLINGSHEAD

Chief Strategy Officer

Jim was appointed as Chief Strategy Officer in May 2011, having joined ResMed as Vice President of Strategy & Business Development in March of 2010.

Prior to joining ResMed, Jim spent almost 18 years in the Strategy Consulting Industry. From 2008 to 2010, he was a Senior Partner in the Strategy and Life Sciences Practices in Deloitte Consulting, based in San Francisco. From 1993 through 2008, he worked at Monitor Group, a leading global Strategy Consulting firm. At Monitor Jim had tours of duty around the globe, including as head of Monitor’s Istanbul office from 1998 to 2000, and Managing Partner for the European Marketing Strategy Practice working out of London from 2000 through 2003. Jim’s consulting experience spans across a range of industries, and includes extensive Life Sciences experience, especially in Biotech.

Jim holds an AB in History and International Relations with Highest Distinction from Stanford University, and an MA and PhD in Political Science from the University of California at Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation.

ANNE REISER

President, Europe

Anne Reiser was appointed President, Europe in March, 2012. She had served as ResMed's Chief Operating Officer - France since 2007, after joining as the Sales Director in 2006. Ms Reiser demonstrated a great track record in building and leading our successful French organization, with both strong sales growth and market share increase.

Prior to joining ResMed, her entire career experience had been in the medical device industry (Mölnlycke, Zimmer, American Home Product). More recently she worked for  Hollister and Medtronic with responsibilities covering both France and finally southern European countries. Ms Reiser has a Masters degree from Ecole Supérieure de Commerce de Clermont-Fd (Business School), and a Bachelor degree of Law from the University of Clermont-Ferrand.

GEOFF NEILSON

President, Respiratory Care Strategic Business Unit

Geoff Neilson has been President, Respiratory Care Strategic Business Unit since May 2011. Mr. Neilson joined ResMed in 2006, becoming Vice President, Sleep Product Development in July 2007. He was appointed Vice President, Ventilation Strategic Business Unit in March 2010 before relocating to the USA in Sept 2010. Prior to joining ResMed, Mr. Neilson was CEO of Milvella Ltd (Ophthalmic devices), General Manager of Magnetic Resonance Diagnostic Technologies. He was Director, Clinical Studies for Telectronics Pacing Systems (USA) and also managed Product Development for Telectronics Australia. He has a B.Sc (Hons I) in Electrical & Electronic Engineering from Heriot-Watt University in Edinburgh.

DAVID PENDARVIS

Chief Administrative Officer and Global General Counsel

David Pendarvis was appointed Chief Administrative Officer in May 2011 and remains Global General Counsel. Mr. Pendarvis has held the roles of Sr. Vice President, Organizational Development since February 2005, and Global General Counsel since he joined ResMed in September 2002, and Corporate Secretary from February 2003. From September 2000 until September 2002, Mr. Pendarvis was a partner in the law firm Gray Cary Ware & Freidenrich LLP, where he specialized in intellectual property and general business litigation. Until September 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis is also a Director on the Board of Sequenom, Inc. He holds a B.A. from Rice University; a J.D., cum laude, from the University of Texas School of Law; and a Masters of Science in Executive Leadership from the University of San Diego.

BRETT SANDERCOCK

Chief Financial Officer

Brett Sandercock has been Chief Financial Officer since January 2006. From November 2004 until December 2005, Mr. Sandercock was Vice President, Treasury and Finance. Before that, Mr. Sandercock was Group Accountant and then Controller from 1998 to November 2004. Prior to his positions at ResMed, Mr. Sandercock was Manager, Financial Accounting and Group Reporting at Norton Abrasives, a division of the French multi-national, Saint Gobain, between March 1996 and August 1998. Mr. Sandercock also held finance and accounting roles from November 1994 to March 1996 at Health Care of Australia, a large private hospital operator in Australia. From 1989 to 1994, Mr. Sandercock worked at PricewaterhouseCoopers in Sydney, specializing in audits of clients predominantly focused on distribution and manufacturing, financial services and technology. Mr. Sandercock holds a B.Ec. from Macquarie University and is a Certified Chartered Accountant.